Clinical Trials Directory

Trials / Completed

CompletedNCT01899261

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Albert Einstein College of Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate feasibility and safety of stereotactic body radiation therapy (SBRT) of the liver for treatment of hepatocellular carcinoma (HCC). SECONDARY OBJECTIVES: I. To evaluate radiographic local response, local control and time to local progression (TTLP) of treated lesions in HCC patients after liver SBRT. II. To evaluate overall survival (OS) and cancer specific survival (CSS) in HCC patients treated with liver SBRT. III. To evaluate explanted irradiated liver tissue (for patients who proceed to liver transplantation) to determine extent of residual tumor and extent of radiation effects within and around the irradiated field. OUTLINE: Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months and then every 6 months for up to 2 years.

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic RadiosurgeryUndergo SBRT

Timeline

Start date
2010-10-07
Primary completion
2016-05-09
Completion
2019-05-01
First posted
2013-07-15
Last updated
2022-11-29
Results posted
2020-01-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01899261. Inclusion in this directory is not an endorsement.